MET Mutation Analysis detects the somatic splice site mutations at exon 14 of the MET gene from formalin-fixed paraffin-embedded tissues (FFPE). MET exon 14 alterations were shown to promote RNA-splicing–based skipping of MET exon 14, which results in activation of MET kinase activity. MET exon 14 alterations have been shown to occur in approximately 3% of lung adenocarcinoma cases and have also been observed in neuroblastoma and gastric cancer cell lines1. Targeted therapies inhibiting MET signaling would be beneficial for patients with MET exon14 alterations.

References
 
  1. Framton et al. “Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug;5(8):850-9